Brief: Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted To Lp-184 In Multiple Ultra Rare Children’S Cancers
23/09/2024 14:24
Sept 23 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA ANNOUNCES THREE U.S. FDA RARE PEDIATRIC
DISEASE
DESIGNATIONS GRANTED TO LP-184 IN MULTIPLE ULTRA RARE CHILDREN’S
CANCERS
Source text for Eikon: ID:nBw9lFqDSa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview